Clinical Correlates of Grey Matter Pathology in Multiple Sclerosis

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2012 Mar 9

PMID 22397707

Citations 27

Authors

Dana Horakova

Tomas Kalincik

Jana Blahova Dusankova

Ondrej Dolezal

Affiliations

Soon will be listed here.

Abstract

Traditionally, multiple sclerosis has been viewed as a disease predominantly affecting white matter. However, this view has lately been subject to numerous changes, as new evidence of anatomical and histological changes as well as of molecular targets within the grey matter has arisen. This advance was driven mainly by novel imaging techniques, however, these have not yet been implemented in routine clinical practice. The changes in the grey matter are related to physical and cognitive disability seen in individuals with multiple sclerosis. Furthermore, damage to several grey matter structures can be associated with impairment of specific functions. Therefore, we conclude that grey matter damage - global and regional - has the potential to become a marker of disease activity, complementary to the currently used magnetic resonance markers (global brain atrophy and T2 hyperintense lesions). Furthermore, it may improve the prediction of the future disease course and response to therapy in individual patients and may also become a reliable additional surrogate marker of treatment effect.

Citing Articles

Brief international cognitive assessment for MS (BICAMS) and NEDA maintenance in MS patients: A 2-year follow-up longitudinal study.

Leveraro E, Cellerino M, Lapucci C, Dighero M, Nasone L, Sirito T Eur J Neurol. 2024; 32(1):e70007.

PMID: 39707758 PMC: 11662165. DOI: 10.1111/ene.70007.

Characteristics of cerebral blood flow in an Eastern sample of multiple sclerosis patients: A potential quantitative imaging marker associated with disease severity.

Zhou Q, Zhang T, Meng H, Shen D, Li Y, He L Front Immunol. 2022; 13:1025908.

PMID: 36325320 PMC: 9618793. DOI: 10.3389/fimmu.2022.1025908.

Seizures and multiple sclerosis‑more than an epidemiological association (Review).

Antal D, Schreiner T, Crihan T, Ignat B, San Antonio-Arce V, Cuciureanu I Exp Ther Med. 2022; 24(5):689.

PMID: 36277158 PMC: 9535632. DOI: 10.3892/etm.2022.11625.

Temporal trends of epilepsy in multiple sclerosis.

Mahamud Z, Burman J, Zelano J Acta Neurol Scand. 2022; 146(5):492-498.

PMID: 35852006 PMC: 9795966. DOI: 10.1111/ane.13671.

Widespread Disruptions of White Matter in Familial Multiple Sclerosis: DTI and NODDI Study.

Gharaylou Z, Sahraian M, Hadjighassem M, Kohanpour M, Doosti R, Nahardani S Front Neurol. 2021; 12:678245.

PMID: 34484098 PMC: 8415561. DOI: 10.3389/fneur.2021.678245.

References

Rovaris M, Judica E, Sastre-Garriga J, Rovira A, Sormani M, Benedetti B . Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler. 2008; 14(4):455-64. DOI: 10.1177/1352458507085129. View

Gilmore C, Bo L, Owens T, Lowe J, Esiri M, Evangelou N . Spinal cord gray matter demyelination in multiple sclerosis-a novel pattern of residual plaque morphology. Brain Pathol. 2006; 16(3):202-8. PMC: 8095912. DOI: 10.1111/j.1750-3639.2006.00018.x. View

Neema M, Stankiewicz J, Arora A, Dandamudi V, Batt C, Guss Z . T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging. 2007; 17 Suppl 1:16S-21S. DOI: 10.1111/j.1552-6569.2007.00131.x. View

Neema M, Arora A, Healy B, Guss Z, Brass S, Duan Y . Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009; 19(1):3-8. PMC: 2762230. DOI: 10.1111/j.1552-6569.2008.00296.x. View

Calabrese M, Rocca M, Atzori M, Mattisi I, Bernardi V, Favaretto A . Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology. 2009; 72(15):1330-6. DOI: 10.1212/WNL.0b013e3181a0fee5. View

Barkhof F . The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002; 15(3):239-45. DOI: 10.1097/00019052-200206000-00003. View

Calabrese M, Filippi M, Rovaris M, Bernardi V, Atzori M, Mattisi I . Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler. 2008; 15(1):36-41. DOI: 10.1177/1352458508096686. View

Weiner H . The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann Neurol. 2009; 65(3):239-48. DOI: 10.1002/ana.21640. View

Tedeschi G, Lavorgna L, Russo P, Prinster A, Dinacci D, Savettieri G . Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology. 2005; 65(2):280-5. DOI: 10.1212/01.wnl.0000168837.87351.1f. View

10.

Calabrese M, Atzori M, Bernardi V, Morra A, Romualdi C, Rinaldi L . Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol. 2007; 254(9):1212-20. DOI: 10.1007/s00415-006-0503-6. View

11.

Dolezal O, Dwyer M, Horakova D, Havrdova E, Minagar A, Balachandran S . Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. Int Rev Neurobiol. 2007; 79:475-89. DOI: 10.1016/S0074-7742(07)79021-9. View

12.

De Stefano N, Matthews P, Filippi M, Agosta F, De Luca M, Bartolozzi M . Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003; 60(7):1157-62. DOI: 10.1212/01.wnl.0000055926.69643.03. View

13.

Peterson J, Bo L, Mork S, Chang A, Trapp B . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50(3):389-400. DOI: 10.1002/ana.1123. View

14.

Bagnato F, Salman Z, Kane R, Auh S, Cantor F, Ehrmantraut M . T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis. Mult Scler. 2010; 16(10):1203-12. DOI: 10.1177/1352458510377223. View

15.

Hayton T, Furby J, Smith K, Altmann D, Brenner R, Chataway J . Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis. J Neurol. 2009; 256(3):427-35. DOI: 10.1007/s00415-009-0110-4. View

16.

Roosendaal S, Moraal B, Pouwels P, Vrenken H, Castelijns J, Barkhof F . Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler. 2009; 15(6):708-14. DOI: 10.1177/1352458509102907. View

17.

Benedict R, Bruce J, Dwyer M, Abdelrahman N, Hussein S, Weinstock-Guttman B . Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol. 2006; 63(9):1301-6. DOI: 10.1001/archneur.63.9.1301. View

18.

Bo L, Vedeler C, Nyland H, Trapp B, Mork S . Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003; 9(4):323-31. DOI: 10.1191/1352458503ms917oa. View

19.

Patti F . Cognitive impairment in multiple sclerosis. Mult Scler. 2008; 15(1):2-8. DOI: 10.1177/1352458508096684. View

20.

Rudick R, Fisher E, Lee J, Simon J, Jacobs L . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999; 53(8):1698-704. DOI: 10.1212/wnl.53.8.1698. View